Abstract
948P - First-line pembrolizumab (pembro) monotherapy for advanced non-clear cell renal cell carcinoma (nccRCC): Updated follow-up for KEYNOTE-427 cohort B
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have